Skip to main content

Disclaimer

In the Downloads section, the ‘Prior Submission’ file reflects the most recent measure submission to the former CBE. This file is provided for transparency. For any questions or clarification, please contact the designated measure steward.

Chronic Kidney Disease with LDL Greater than or equal to 130 – Use of Lipid Lowering Agent

CBE ID
0627
Endorsement Status
1.0 New or Maintenance
1.1 Measure Structure
Previous Endorsement Cycle
Is Under Review
No
1.6 Measure Description

The percentage of patients with chronic kidney disease stage 5 and an LDL greater than or equal to 130 mg/dl that have a current refill for a lipid lowering agent.

    Measure Specs
      General Information
      1.14 Numerator

      Patients with a current refill for a lipid lowering agent.

      1.15 Denominator

      All patients, ages 18 and older, diagnosed with chronic kidney disease stage 5, dialysis, or kidney transplant, and an LDL level above 130 mg/dL.

      Exclusions

      Specific Exclusions:
      None
      General Exclusions:
      • Evidence of metastatic disease or active treatment of malignancy (chemotherapy or radiation therapy) in the last 6 months;
      • Patients who have been in a skilled nursing facility in the last 3 months
      • Patient or provider feedback indicating allergy or intolerance to the drug in the past
      • Patient or provider feedback indicating that there is a contraindication to adding the drug

      Most Recent Endorsement Activity
      Measure Retired and Endorsement Removed Renal Consensus Standards Endorsement Maintenance 2011
      Initial Endorsement
      Last Updated
      Removal Date
      Steward Organization
      ActiveHealth Management
      Steward POC email
      Steward Organization Copyright

      This information, including any attachments hereto, is the sole, exclusive, proprietary and confidential property of ActiveHealth Management, Inc., and is for the exclusive use of The National Quality Forum. Any use, copying, disclosure, dissemination or distribution by anyone other than the National Quality Forum is strictly prohibited.

                Public Comments